Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27851751)
Watch
English
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
22452895
retrieved
13 November 2016
title
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
(English)
1 reference
stated in
PubMed
PubMed ID
22452895
retrieved
13 November 2016
main subject
phase II clinical trial
0 references
patient
0 references
adenocarcinoma
1 reference
based on heuristic
inferred from title
author
Sai-Hong Ignatius Ou
series ordinal
6
object named as
Sai-Hong Ignatius Ou
0 references
Lecia V Sequist
series ordinal
10
object named as
Lecia V Sequist
0 references
author name string
James Chih-Hsin Yang
series ordinal
1
0 references
Jin-Yuan Shih
series ordinal
2
0 references
Wu-Chou Su
series ordinal
3
0 references
Te-Chun Hsia
series ordinal
4
0 references
Chun-Ming Tsai
series ordinal
5
0 references
Chung-Jen Yu
series ordinal
7
0 references
Gee-Chen Chang
series ordinal
8
0 references
Ching-Liang Ho
series ordinal
9
0 references
Arkadiusz Z Dudek
series ordinal
11
0 references
Mehdi Shahidi
series ordinal
12
0 references
Xiuyu Julie Cong
series ordinal
13
0 references
Robert M Lorence
series ordinal
14
0 references
Pan-Chyr Yang
series ordinal
15
0 references
Vincent A Miller
series ordinal
16
0 references
publication date
May 2012
0 references
published in
Lancet Oncology Commission
0 references
volume
13
0 references
page(s)
539-48
0 references
issue
5
0 references
cites work
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Detection of mutations in EGFR in circulating lung-cancer cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Living with imperfection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Screening for epidermal growth factor receptor mutations in lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(12)70086-4
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1386281
OpenCitations bibliographic resource ID
1386281
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1386281
PubMed ID
22452895
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1386281
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit